Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies  

Scientists Uncover Central Role of N-Myristoylation in Senescence

  • Data published today in Nature Cell Biology by Myricx collaborators at the MRC-LMS (Laboratory of Medical Sciences) led by Prof. Jesús Gil have uncovered the central role of N-myristoyltransferase (NMT) as a druggable pathway in senescence
  • Myricx’s proprietary NMT inhibitors (NMTis) were shown to have a potent senolytic effect, selectively eliminating senescent non-dividing cells
  • Clear differentiation for Myricx’s NMTi proprietary payloads for antibody-drug conjugates (ADCs) with dual senolytic as well as cytotoxic MOA has the potential to induce deeper and more durable tumour responses
  • Myricx has licensed exclusive IP rights to develop NMTis for senescence applications from Imperial College Innovations Limited and UKRI 

London, UK, 27 November 2023 – Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase (NMT) inhibition, is pleased to announce the publication today of ground-breaking research in Nature Cell Biology1 by its collaborators at the MRC-LMS (Laboratory of Medical Sciences) that has uncovered the central role of
NMT as a druggable pathway in senescence.

Cellular senescence, the process when cells stop dividing and undergo distinct physiological changes is implicated in many diseases. Senescent or so called ‘zombie’ cells can have deleterious effects on tissue function as they are persistent and secrete many proteins. In tumours, these proteins can drive chronic inflammation, metastasis, drug resistance and tumour growth. Small-molecule drugs that selectively eliminate senescent cells, known as senolytics, provide a promising novel strategy for treating multiple diseases, including cancer, fibrotic diseases, and age-related conditions.

The research, funded by UKRI MRC and CRUK, involved a major collaborative study led by Myricx’s Scientific Consultant and Collaborator, Professor Jesús Gil, lead author of the study and Head of the Senescence Research Group at MRC-LMS, together with Myricx co-founder Professor Ed Tate, and 18 other scientists, discovered that small molecule NMTis can selectively kill senescent cancer cells.

Overall, the study demonstrated that senescent cells rely on a hyperactive secretory apparatus and that this secretory phenotype is dependent on NMT and inhibiting NMT kills senescent cells. This discovery opens up the potential to treat various senescence-associated diseases with NMTis, including cancer.

At a more detailed cellular level, this study demonstrated that coatomer complex I (COPI) vesicle formation in senescent cells is a process (vulnerability/liability) that can be targeted with COPI inhibitors, however these senolytic drugs have poor pharmacological properties. Compelling data then showed that Myricx’s proprietary potent NMTis are non-toxic senolytics that mirror the effects of (phenocopy) COPI inhibition by selectively eliminating senescent cells with improved outcomes in different in vivo proof-of-concept cancer models. Specifically, NMTi targets ARF1, a key regulator of COPI vesicle formation that needs a lipid modification (called myristoylation) to be functional.

Professor Jesús Gil, MRC Laboratory of Medical Sciences, and Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London added, “Our team has long been looking into senolytic targets that effectively and selectively kill senescent cells.
In a previous study, we showed the potential of repurposing existing drugs, but there are only limited drugs to choose from. In this study, we expanded our selection pool to be much larger by seeking targets in over 7,000 ‘druggable’ genes. We were thrilled to reveal previously unknown vulnerabilities of senescent cells. This opens up new possibilities for treating age-related diseases and cancer.

“A big part of the success of the project was thanks to the close collaboration with Ed Tate’s lab and all of the Myricx team. Roberto Solari, a Myricx Bio co-founder, was always there to give advice and see how we could push the project forward.”

Prof Ed Tate, Myricx co-founder and Chair of its Scientific Advisory Board, and GSK Chair of Chemical Biology at Imperial College London and a Satellite Group Leader at the Francis Crick Institute said, “Our findings suggest that NMT inhibition could be a game-changer in senolytic therapy. Our potent, selective, in vivo active small molecule NMTis open exciting avenues for further research and development, as the first senolytic targeting protein lipidation.”

CEO of Myricx BIO, Dr Robin Carr said “The senolytic properties that this research has demonstrated gives our NMTi-ADCs the potential for a highly differentiated profile not addressed by any other ADCs. Combined with the cytotoxic effect of NMTis, the senolytic mechanism has the potential to induce deeper and more durable responses in treating tumours than purely cytotoxic payloads. We look forward to exploring this as we advance our drugs into clinical trials.”

Myricx has patents pending and licensed exclusive IP rights to develop NMTis as novel drugs including in senescence applications from Imperial College Innovations Limited and UKRI. The company has validated its NMTi payload platform having demonstrated in vivo pre-clinical efficacy for three NMTi-ADCs in its pipeline (B7-H3-NMTi, TROP2-NMTi, HER2-NMTi) showing complete and durable tumour regressions in multiple cancer models.

Read Nature Cell Biology 2023. Nov 27. News & Views, COPIng with senescence.

  1. COPI vesicle formation and N-myristoylation are targetable vulnerabilities of senescent cell, Nature Cell Biology, 27 November 2023 – www.nature.com/articles/s41556-023-01287-6

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour associated antigens and cancer cell types.

Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Sofinnova Partners and Brandon Capital Partners.

Follow us on LinkedIn

For further information please contact

At the Company
Dr Robin Carr, CEO
Myricx Bio
info@myricxbio.com

Media Enquiries
Sue Charles
Charles Consultants
sue@charles-consultants.com
+44 (0)7986 726585

Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics

London, UK and Shanghai, China, 21 November 2023 – Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), and WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announce that they have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on WuXi Bio’s integrated technology platforms.

Under the terms of the agreement, Myricx will develop the antibody into a first-in-class ADC based on its NMTi payload platform, which has a highly differentiated profile over standard payload classes, including microtubule and topoisomerase inhibitors. Myricx intends to progress the ADC through preclinical and clinical development for difficult-to-treat solid tumours. WuXi Bio will receive an upfront payment and will be eligible for development and commercialisation milestone payments, as well as royalties on net sales.

NMT is an enzyme that adds a specific lipid modification to several protein targets key to cancer cell survival. Myricx recently highlighted the power of its NMTi payload platform across multiple tumour-associated antigens including B7-H3, TROP2, and HER2, with preclinical data presented at the 14th Annual World ADC conference in San Diego for which Myricx won the prize for Best Poster.

This is the second antibody license agreement that Myricx has entered into with a global company in the past few months as the Company builds out its pipeline of NMTi-ADCs.

Myricx CEO Dr Robin Carr said, “We are delighted to have reached this agreement with WuXi Bio, one of the top biologics CRDMOs globally. We believe that combining this leading antibody with our novel NMTi-based payload will create an ADC with significant clinical differentiation in solid tumours. Based on our positive preclinical data we believe NMTi-ADCs offer a highly differentiated mechanism of action, superb efficacy, and good tolerability across different cancer targets.”

Dr Chris Chen, CEO of WuXi Biologics, commented, “This license agreement with Myricx is another testament of our proprietary integrated platform and the ‘R’ in our CRDMO business model. We are looking forward to enabling global clients to develop more first-in-class and best-in-class biologics drugs for the benefits of patients worldwide.”

Myricx is a spin-out from two of the UK’s leading biomedical research organisations: Imperial College London and the Francis Crick Institute; founded to develop drugs based on the unique insights into NMT biology made by its founders Professors Ed Tate and Roberto Solari, with seed financing from Sofinnova Partners and Brandon Capital.

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour associated antigens and cancer cell types.

Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Sofinnova Partners and Brandon Capital Partners.

Follow us on LinkedIn

About WuXi Biologics – www.wuxibiologics.com

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2023, WuXi Biologics is supporting 621 integrated client projects, including 22 in commercial manufacturing.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For further information please contact

At the Company
Dr Robin Carr, CEO
Myricx Bio
info@myricxbio.com

Media Enquiries
Sue Charles
Charles Consultants
sue@charles-consultants.com
+44 (0)7986 726585

Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

London, UK 15 November 2023 – Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors. Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space.

Dr Martin was instrumental in co-founding ADC Therapeutics (NYSE: ADCT) in Jan 2012 and served as its CEO since inception until May 2022. Under his leadership, ADC Therapeutics grew from a private biotech start-up to a New York Stock Exchange (NYSE) listed leader in the field of ADCs with products on the global market. Chris previously co-founded and led two other biotech companies: Spirogen Ltd, an innovator of ADC payload technology, which was acquired by MedImmune, now part of AstraZeneca; and Sciona, Inc. a provider of personalised gene-based health and nutrition analyses. Alongside his role as Chairman of Myricx, he is also Chairman of the Board of Tokamak Energy Ltd, and Tagworks Pharmaceuticals BV, and a Director on the Board of Osivax SAS.

Dr Martin succeeds Prof Roberto Solari, co-founder of Myricx who is stepping down from the board but will remain closely involved as a consultant to the company contributing his extensive drug discovery experience and knowledge.

A Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow, Dr Martin holds a bachelor’s degree in chemical engineering from Aston University, a DPhil in Engineering Science from the University of Oxford, and an MBA from IMD Business School.

Dr Robin Carr, Myricx CEO and Board Director, said, “We are thrilled that Chris has joined our Board and taken on the role of Chairman. He brings first-hand experience of successfully building biotech companies, and his wealth of insights and know-how in the ADC industry are unrivalled. Chris successfully translated ADC technology from the lab bench and discovery stages to regulatory approved commercial products reaching cancer patients across global markets. As we are building out our pipeline of differentiated NMTi-ADCs and progressively expanding our preclinical activities towards clinical development, Chris’s experience and guidance will be invaluable.

“I would also like to thank Roberto for his excellent contribution to the company most recently as executive chair, and we look forward to his continued active involvement as a consultant and collaborator.”

Dr Chris Martin, Chairman of Myricx said; “There is a compelling clinical need for new ADC payloads with the potential to expand ADC’s therapeutic window, and I am really impressed with Myricx’s novel NMTi payload platform, which has demonstrated a highly differentiated profile over standard payload classes. The platform has the potential to generate proprietary first-in-class NMTi-ADCs and the company’s lead candidates have shown positive preclinical data including superb efficacy, and good tolerability across different cancer targets. It is an incredibly exciting time to join the Myricx board and I look forward to working closely with its talented team, board and investors, bringing my experience of partnering ADC payloads with pharma from Spirogen and developing in house ADCs to market from ADC Therapeutics.”

To support the progression of its preclinical pipeline towards the clinic for difficult to treat solid tumours, Myricx has also recently strengthened its leadership team by appointing Dr Francesca Zammarchi, a cancer biology and ADC expert, as CSO and Dr Robert McLeod, a specialist in ADC clinical development, to the newly created position of VP Clinical Development.

Myricx is a spin-out from two of the UK’s leading biomedical research organisations: Imperial College London and the Francis Crick Institute; founded to develop drugs based on the unique insights into NMT biology made by its co-founders Professors Ed Tate and Roberto Solari, with seed financing from Sofinnova Partners and Brandon Capital.

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour associated antigens and cancer cell types.

Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Sofinnova Partners and Brandon Capital Partners.

Follow us on LinkedIn

For further information please contact

At the Company
Dr Robin Carr, CEO
Myricx Bio
info@myricxbio.com

Media Enquiries
Sue Charles
Charles Consultants
sue@charles-consultants.com
+44 (0)7986 726585

Myricx Bio Wins Best Poster at World ADC

London, UK, 19 October 2023 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce that it has won the award for Best Poster at the 14th Annual #WorldADC conference, San Diego, California, held from October 16-19, 20231.

The poster showcased new data on the preclinical efficacy of Myricx’ proprietary N-Myristoyltransferase inhibitor (#NMTi) payload platform and was selected against a large field judged by experts in the ADC field.

Accepting the award, CEO, Dr Robin Carr said: “World ADC is the preeminent gathering of experts in the ADC field. This award is an endorsement of the huge potential our platform has to create an important new class of ADC medicines.”

The data presented showed complete tumour regressions across a range of solid tumour xenograft models for NMTi-ADCs targeting three clinically validated tumour-associated antigens (B7-H3, TROP2 and HER2), as well as excellent bystander activity, and encouraging preliminary safety findings.

Congratulations to Myricx team and authors on the poster who have contributed to this work: Robin Carr, Josephine Walton, Folake Orafidiya, Nikki D’Arcy, Francesco Falciani, Sarah Spear, Katie Tyson, Iain McNeish, Tim Ritchie, Andy Bell, Ed Tate, and Roberto Solari.

1. Poster Details:

Title: N-Myristoyltransferase (NMT) inhibitors as completely novel payloads for Antibody Drug Conjugates, deliver extensive tumor regression at well tolerated doses.

Presented by: Dr Robin Carr, CEO Myricx Bio

Session: Scientific Program, Tuesday October 17, Evening Session

A copy of the poster is available on our website – HERE

 

 

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour associated antigens and cancer cell types.

Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Sofinnova Partners and Brandon Capital Partners.

Follow us on LinkedIn

For further information please contact

At the Company
Dr Robin Carr, CEO
Myricx Bio
info@myricxbio.com                                                                             

Media Enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 726585

Myricx Bio to Present Preclinical Data Validating NMTi as a Novel ADC Payload Class

  • Preclinical efficacy studies validate Myricx Bio’s proprietary N-Myristoyltransferase inhibitor (NMTi) payload platform
  • Complete tumour regressions across a range of solid tumour xenograft models for NMTi-ADCs targeting three clinically validated tumour-associated antigens (B7-H3, TROP2 and HER2)
  • Encouraging initial non-human primate tolerability data presented
  • Data presentation at the 14th Annual World ADC Conference in San Diego

London, UK, 17 October 2023 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is presenting preclinical in vivo efficacy data for its NMTi-ADC platform and pipeline at the 14th Annual World ADC Event, San Diego, California, held from October 16-19, 20231.

Myricx’s payload platform is based on proprietary potent small molecule NMT inhibitors (NMTi). In the poster presentation Myricx reported data for three NMTi-ADCs in its pipeline. These comprise B7-H3-NMTi, TROP2-NMTi, and HER2-NMTi.

B7-H3-NMTi demonstrated complete and durable tumour regressions in multiple models of aggressive prostate cancer refractory to Topo1i-based ADCs. Initial toxicology is currently under evaluation in non-human primates.

TROP2-NMTi also demonstrated complete and durable tumour regressions in breast cancer models refractory to Topo1i-based ADCs; including the ability to regress large and established tumours that had prior exposure to a Topo1i-based ADC.

HER2-NMTi demonstrated complete efficacy, and an encouraging tolerability profile in rodents and non-human primates. In addition, it showed potent bystander activity, and efficacy in patient-derived xenograft (PDX) organoid models with a broad range of antigen expression levels.

Myricx CEO, Dr Robin Carr said: “The preclinical data generated by our three NMTi-ADCs give us confidence that the NMTi payload platform has the potential to deliver an important new ADC payload class in the treatment of solid tumours. We are looking forward to advancing our pipeline of ADCs and generating clinical data.”

  1. Poster Presentation Details:

Title: N-Myristoyltransferase (NMT) inhibitors as completely novel payloads for Antibody Drug Conjugates, deliver extensive tumor regression at well tolerated doses.

Presented by: Dr Robin Carr, CEO Myricx Bio

Session: Scientific Program, Tuesday October 17, Evening Session

A copy of the poster is available on our website – HERE

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour associated antigens and cancer cell types.

Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Sofinnova Partners and Brandon Capital Partners.

Follow us on LinkedIn

For further information please contact

At the Company
Dr Robin Carr, CEO
Myricx Bio
info@myricxbio.com                                                                                                            

Media Enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 726585

Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO

London, UK, 4 October 2023 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs), today announces the appointment of Francesca Zammarchi Ph.D. as Chief Scientific Officer (CSO).

Dr Zammarchi joins Myricx as it accelerates the development of its pipeline of ADCs based on its first-in-class N-myristoyltransferase inhibitor (NMTi) payload platform. She brings over two decades of cancer biology research experience, including developing ADCs, gained working in the biopharma industry and in academia. At Myricx, as a senior member of the Leadership Team, she will be responsible for the company’s internal and partnered scientific programmes.

She joins Myricx from ADC Therapeutics SA (NYSE: ADCT) where she served as Head of Preclinical Pharmacology. During her 10 years at ADC Therapeutics, she worked as a cancer biologist actively involved in the discovery and evaluation of new projects for the company’s portfolio, with responsibility for preclinical pharmacology studies, and progressed multiple ADCs with novel payloads through IND to BLA. Her earlier academic career included Research Associate at Memorial Sloan-Kettering Cancer Centre, and Research Associate and Visiting Fellow at Mount Sinai School of Medicine. Dr Zammarchi gained her Ph.D. in experimental and molecular oncology and her B.Sc. in molecular biology from the University of Pisa, Italy.

Welcoming Francesca to the company, Myricx CEO Dr Robin Carr said: “As we advance our unique ADC pipeline against important cancer targets, Francesca’s impressive background in ADC discovery and development provides an ideal skillset to lead our programmes as CSO. We believe our first-in-class selective cytotoxic payloads based on potent inhibitors of N-myristoyltransferase (NMT) will provide important advantages in the development of differentiated ADC therapeutics.”

Dr Francesca Zammarchi, CSO at Myricx, said: “Having spent over a decade in R&D of novel ADC payloads, I am impressed by Myricx’s preclinical data showing the potential of NMT inhibitors to become the backbone of a new class of ADC drugs with selective cancer cell killing activity. I look forward to working with the Myricx team to expand and advance its ADC discovery pipeline.”

Dr Zammarchi will join the Myricx Bio team at its headquarters in Kings Cross, London.

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody-drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour-associated antigens and cancer cell types.

Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Sofinnova Partners and Brandon Capital Partners.

Myricx Bio is the trading name of Myricx Pharma Limited.

Follow us on LinkedIn

For further information please contact

At the Company
Dr Robin Carr, CEO
Myricx Bio
info@myricxbio.com                                                                                                                     

Media Enquiries
Sue Charles
Charles Consultants
sue@charles-consultants.com
+44 (0)7986 726585

 

Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development

London, UK, 13 September 2023 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces the appointment of Dr. Robert McLeod as Vice President (VP) Clinical Development.

In this new role, Dr. McLeod joins the Leadership Team and will be responsible for developing the clinical strategy and IND submissions as the company advances its targeted ADC pipeline towards clinical trials.

With over 20 years of drug development experience in the US and Europe, Dr. McLeod brings extensive expertise in ADC clinical development, having previously been a Senior Director and Global Clinical Lead at Daiichi Sankyo where he worked on several ADCs across multiple solid tumour types.

Prior to Daiichi Sankyo, Dr. McLeod was a Research Physician at Cancer Research UK’s Centre for Drug Development, where he focused on translational medicine and early phase oncology trials across a range of solid and haematological malignancies. In addition, he has also held roles at Emergent BioSolutions, Novartis and Chiron after having trained and worked as a physician in both Australia and the UK at the beginning of his career.

Dr. McLeod earned his medical degree at the University of Melbourne, holds an MBA from ESCP Business School in Paris, a Diploma in Pharmaceutical Medicine, and is a Fellow of the UK Faculty of Pharmaceutical Medicine.

Welcoming Robert to the company, Myricx CEO Dr. Robin Carr said: “We are very pleased to have attracted Robert to the company. He brings significant experience in the translational development of oncology drugs and in particular ADCs. This is important as we advance our ADC pipeline of proprietary monoclonal antibodies (mAbs) against important cancer targets conjugated to our first-in-class selective cytotoxic payloads based on potent inhibitors of N-myristoyltransferase (NMT), a completely novel concept in the ADC space.”

Dr. Robert McLeod, Vice President Clinical Development at Myricx, said: “I am excited by the potential of NMT inhibitors as ADC payloads that can be exploited as targeted therapies with selective cancer cell killing via a unique mechanism of action. NMTi-based cytotoxic payloads will enable us to develop best-in-class ADCs to meet significant clinical needs in oncology, and I look forward to working with the team towards this goal.”

To accommodate its expansion, Myricx has recently moved into its office headquarters at the GridIron Building in London’s fast growing biotech cluster around Kings Cross. In addition, in line with its strategy to focus on the development of NMT inhibitors as novel cytotoxic payloads for ADCs, the Company has recently rebranded from Myricx Pharma to Myricx Bio.

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour associated antigens and cancer cell types.

Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Sofinnova Partners and Brandon Capital Partners.

Myricx Bio is the trading name of Myricx Pharma Limited.

Follow us on LinkedIn

For further information please contact

At the Company

Dr Robin Carr, CEO
Myricx Bio
info@myricxbio.com                                                                                                             

Media Enquiries

Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 726585

 

Myricx Enters into Antibody License Agreement with Biocytogen

London, UK 07 September 2023 – Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), today announces an antibody license agreement with Biocytogen Pharmaceuticals (Beijing) Co., Ltd (‘Biocytogen’, HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics.

The agreement will enable Myricx to develop and commercialize ADCs based on an antibody developed using Biocytogen’s proprietary RenMice® platform and will expand Myricx’s ADC pipeline of proprietary monoclonal antibodies (mAbs) against important cancer targets to which it conjugates its first-in-class selective cytotoxic payloads based on potent inhibitors of N-MyristoylTransferase (NMT), a completely novel concept in the ADC space.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival. Myricx is developing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour associated antigens and cancer cell types.

Under the terms of the agreement, Myricx will provide its proprietary linker and NMTi payload and Biocytogen will conjugate them with its RenMice®-derived fully human antibody to make ADCs. Biocytogen will carry out feasibility tests for these ADCs as CRO services, and upon option exercise, Myricx will be responsible for further development and commercialization. Biocytogen will receive an upfront payment and subject to exercise, Biocytogen will be eligible to receive development and commercialisation milestone payments, as well as single-digit royalties on net sales.

Myricx CEO Dr Robin Carr said: “We are delighted to have reached this agreement with Biocytogen with ground-breaking technology to develop novel antibodies for use in drug development. We believe that the combination of its antibody with our novel NMTi-based selective cytotoxic payloads will enable us to develop best-in-class ADCs to meet significant clinical needs in oncology. NMT inhibitors represent a novel class of ADC payloads that can be exploited as targeted therapies in cancer. Based on our positive proof of concept data we believe that ADC-NMTi offer huge potential for selective cancer cell killing via its unique mechanism of action.”

“Thanks to Myricx’ recognition of our antibody assets, preclinical discovery expertise and CMC capabilities,” said by Dr. Yuelei Shen, President and CEO of Biocytogen. “Myricx is a leading expert in NMTi payloads, and we believe that the combination of both company’s strengths will result in ADC drugs with first-in-class and best-in-class potentials.”

Myricx is a spin out from two of the UK’s leading biomedical research organisations, Imperial College, London and the Francis Crick Institute founded to develop drugs based on the breakthrough discoveries and the unique insights into NMT biology made by its founders Professors Ed Tate and Roberto Solari, with seed financing from Sofinnova Partners and Brandon Capital.

-Ends-

Notes to Editors:

About Myricx Bio – www.myricxbio.com

Myricx Bio (“Myricx”) is a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival. Myricx is advancing a pipeline of ADCs to address serious unmet needs in oncology based on its NMT inhibitor (NMTi) payload chemistry platform and has demonstrated excellent preclinical efficacy and safety across multiple solid tumour associated antigens and cancer cell types.

Based in London, Myricx is a spin out from Imperial College London and the Francis Crick Institute with investment from Sofinnova Partners and Brandon Capital Partners.

Myricx Bio is the trading name of Myricx Pharma Limited.

Follow us on LinkedIn

About Biocytogen – http://en.biocytogen.com.cn

Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum (RenMiceTM HiTS Platform). As of June 30, 2023, 50 therapeutic antibody co-development/out-licensing/transfer agreements and 42 target-nominated RenMiceTM licensing projects have been established worldwide, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen’s pipeline is comprised of 10 core assets, with partnerships established for multiple clinical assets. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg).

For further information, please contact:

At the Company
Dr Robin Carr, CEO
Myricx Bio
info@myricxbio.com                                                                                                                

Media Enquiries
Sue Charles, Charles Consultants
sue@charles-consultants.com
+44 (0)7986 726585

 

Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi

  • New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi) as a completely novel ADC payload (see poster 2635)2
  • New biology reveals mode of action (MoA) for NMTi via unfolded protein response (UPR) stress pathways in cancer cells (see poster 4871)3 and ability of NMTi to re-programme tumour-associated macrophages into anti-cancer phenotype (see poster 439)1

London, UK, 17 April 2023 – Myricx Pharma (‘Myricx’), an oncology drug discovery company focused on developing precision medicines based on its N-myristoyltransferase (NMT) platform has unveiled its antibody drug conjugate (ADC) programme, presenting promising in vivo data at the American Association for Cancer Research’s Annual Meeting, AACR 2023, April 14-19, Florida.

NMT inhibitors (NMTi) have previously been shown to inhibit viability and growth of haematological cancers. Myricx’s novel highly potent NMTi are selectively cytotoxic in multiple cancer cell lines as well as exhibiting tumour regression in in vivo models of both haematological and solid cancers. Myricx has also developed a transcriptional signature which predicts cancer cell sensitivity to NMTi with high confidence.

Myricx’s advanced chemistry offers the potential for the development of NMTi as a novel payload on a wide range of existing linker and antibody ADC technologies. A unique feature of NMTi-ADCs is that they contain two targeting mechanisms: a monoclonal antibody (mAb) that targets the payload to antigen positive cancer cells; and selectivity for specific cancers with high intrinsic sensitivity to NMTi. Myricx has data elucidating the mechanism of this sensitivity.

Myricx’s most advanced ADC, MYX2449, is a selective and ultrapotent NMTi conjugated via a cleavable linker to trastuzumab (HER2+ mAb). Positive in vitro and in vivo data presented at AACR2 demonstrate MYX2449 cytotoxic potency in selective cancer cell lines, anti-tumour efficacy in both high and low HER2 expressing cancers, with tolerability >10 times its efficacious dose in in vivo models.

As a proof of concept (PoC) for its NMTi-ADC approach, Myricx tested MYX2449 trastuzumab-NMTi ADC in in vivo models of gastric cancer (GC) and breast cancer (BC), as many of these cancers express HER2 and also express the NMTi sensitivity signature. MYX2449 delivered differentiated activity and improved efficacy compared to the gold standard ADC trastuzumab-deruxtecan in a GC model with excellent tumour shrinkage at 5mpk in the xenograft and excellent cyno tolerability at the highest dose, 20mpk. Similar efficacy was obtained in a BC xenograft model.

Encouraged by these positive PoC results, Myricx is now exploring a range of ADCs in further hard-to-treat solid cancers that express both the NMTi sensitivity signature and ADC-compatible antigens.

Myricx CEO Dr Robin Carr who presented the ADC-NMTi poster at AACR said “NMT inhibitors represent a novel class of ADC payloads that can be exploited as targeted therapies in cancer. Based on our positive PoC data we believe that ADC-NMTi offer huge potential for selective cancer cell killing via its unique mechanism of action.”

Myricx is a start-up from two of London’s leading biomedical research organizations, Imperial College London and the Francis Crick Institute. Myricx scientists and founding collaborators were the first to identify that inhibition of NMT is highly effective in the treatment of MYC-driven cancer models acting through the unfolded protein response (UPR). UPR stress is a known vulnerability of cancer and Myricx is now using its discoveries to build a proprietary pipeline of targeted cancer therapies. The company is developing NMTi as small molecule drugs as well as novel selective cytotoxic payloads for ADCs.

In addition to the poster on its lead ADC programme, scientists from Myricx’s collaborators presented two posters on Myricx’s small molecule programmes and NMT biology, including in vivo reprogramming of tumour-associated macrophages to an anticancer phenotype by modulating NMT activity1 and how deregulation of MYC-family proteins sensitizes cancers to NMT inhibition, resulting in the identification of NMTi sensitivity and mechanism.3

Professor Ed Tate, Myricx co-founder and lead author of the posters presented by the Imperial College London/Francis Crick Institute teams said “NMT is a hot emerging drug target in cancer and Myricx has developed high-quality proprietary chemical inhibitors of NMT that have led to breakthrough discoveries and unlocked an unexpected and unique mechanism of cancer cell killing, specific to cancers with vulnerabilities associated with the unfolded protein response. Furthermore, we have recently shown that NMTi has the potential to drive anti-tumour innate immune responses, including the reprogramming of tumour-associated macrophages in the tumour microenvironment.

“These discoveries alongside the massive potential of NMTi as a selective ADC payload pave the way for novel and highly efficacious treatments for patients.”

1.     Poster number: 439: From foe to friend: In vivo reprogramming of tumour-associated macrophages to an anti-cancer phenotype by modulating N-myristoyltransferase activity – presented by @Wouter Kallemeijn, Francis Crick Institute/Imperial College London
New Drug Targets 16 April 1:30 PM Section 16 board 3

2.     Poster number: 2635: N-Myristoyltransferase (NMT) inhibitors as novel potent payloads for antibody drug conjugates – presented by our CEO @Robin Carr
Antibody Technologies session 17 April, 1:30 PM Section 13 board 3

3.     Poster number: 4871:  Dysregulation of MYC-family proteins sensitizes cancers to NMT inhibition: identification of NMTi sensitivity and mechanism – presented by @James Zhang, ICR/Imperial College London
Anticancer Approaches Targeting Signal Transduction Pathways 18 April 1:30 PM Section 13 board 14

Copies of these posters will be available on our website after they have been presented – view posters

-Ends-

Notes to Editors:

About Myricx Pharma – www.myricxpharma.com

Myricx Pharma Ltd (“Myricx”) is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT) for the treatment of cancer, both directly and as selective cytotoxic payloads for antibody drug conjugate (ADC) drugs.

Operating as a mainly virtual company based in London, UK, Myricx was founded in 2019 based on discoveries made at Imperial College London and the Francis Crick Institute by its co-founders Prof Ed Tate, Dr Andrew Bell and Dr Roberto Solari. The Company has raised an initial £4.5million in seed investment from Sofinnova Partners and Brandon Capital Partners. Myricx has the rights to key NMT discoveries, and composition-of-matter and use patents of its scientific co-founders through exclusive license agreements with Imperial College London.

Follow us on LinkedIn.

About Myristoylation

Myristoylation is a lipid modification to a specific group of target proteins in a cell. It involves the attachment of myristic acid, a 14-carbon fatty acid, to a protein’s N-terminal glycine residue. This process is catalyzed by the ubiquitous eukaryotic enzyme, N-myristoyltransferase (NMT), which uses myristoyl-coenzyme A (CoA) as a substrate.

Myristoylation is an irreversible change to proteins and plays a vital role in protein–protein interactions, targeting proteins to cytoplasmic and plasma membranes, and regulating cellular signaling pathways in several biological processes. It is also known to be involved in a range of diseases including cancer.

For Further information, please contact:

At the Company
Dr Robin Carr, CEO, Myricx Pharma, info@myricxbio.com

Media Enquiries
Sue Charles, Charles Consultants, sue@charles-consultants.com, +44 (0)7986 726585

Myricx Pharma Announces Board and Executive Appointments

  • Rachael Brake, PhD joins the board as independent non-executive director, bringing significant drug development experience, notably from Takeda, Amgen, Millennium
  • Co-founder Professor Ed Tate transitions from CSO to Chairman of the SAB, remaining as a board director
  • Robin Carr, PhD steps up to CSO from his previous position as CDO

Stevenage, UK, April 20 2021 – Myricx Pharma (‘Myricx’), a drug discovery company focused on developing small molecule inhibitors that selectively target the human
N-myristoyltransferases (NMT) in cancer, today announces expansion of its board with the addition of Rachael Brake, PhD as independent non-executive director, alongside R&D leadership role changes: Robin Carr, PhD, previously Chief Development Officer (CDO) is appointed Chief Scientific Officer (CSO); and Co-founder Professor Ed Tate transitions to Chairman of the scientific advisory board (SAB).

Rachael Brake, PhD is a molecular and cellular biologist and a highly experienced drug developer across roles in bio/pharma organisations including Amgen, Millennium and, most recently, Takeda Pharmaceuticals where she currently serves as the Head of US Medical Affairs in Oncology. Full bio HERE.

Welcoming Rachael to the board Roberto Solari, PhD, Chairman, Chief Executive Officer and Co-founder said:

“Rachael brings significant pharmaceutical research and development experience to the Board having a successful career focussed on clinical development translating basic research concepts into effective clinical development strategies. This experience will help steer Myricx as we progress our novel NMT inhibitors towards IND enabling studies.”

Robin Carr, PhD CSO, succeeds co-founder Professor Ed Tate PhD who steps back from his executive role in the company to focus on his academic research at Imperial College London and the Francis Crick Institute. Professor Tate is the world leader in the biology and chemistry of NMT. It was his discoveries of NMT as a novel and emerging drug target for a wide range of oncology and viral indications that lead to the formation of Myricx in 2019. The company maintains collaborations with Imperial College and The Crick, and Professor Tate continues to contribute his expertise as a scientific advisor and chairman of the SAB. He retains his role on the Myricx board of directors.

With over 30 years of experience in drug discovery, Robin is a widely regarded industry veteran and thought leader in innovative/novel drug discovery gained at Glaxo Wellcome, GSK and Astex Therapeutics. See bio HERE.

Commenting on Robin’s change of leadership role to CSO, Dr Solari said:

“During his career Robin has contributed to numerous discovery programs that have progressed into the clinic, two of which went on to become launched drugs within oncology. In addition to his previous responsibilities, Robin also provides scientific leadership, translating our founding discoveries into promising oncology drug candidates.”

Myricx is a start-up from the UK’s leading biomedical research organisations and is pursuing NMT inhibition in a variety of indications with an initial focus in oncology exploiting novel breakthrough discoveries that identified that inhibition of NMT results in specific cancer cell killing via an unexpected and unique mechanism. Myricx has discovered that its NMT inhibitors are proving to be highly effective in the treatment of MYC-driven cancer models. Until now MYC was considered to be undruggable.

-Ends-

Notes to Editors:

About Myricx Pharma – www.myricxpharma.com

 

Myricx Pharma Ltd (“Myricx”) is a small molecule drug discovery company engaged in developing novel proprietary inhibitors of human N-myristoyltransferases (NMT), with a primary focus in oncology but also exploring potential applications across other diseases.

Myricx operates from the Stevenage Bioscience Catalyst facility, UK, and was founded in 2019 based on discoveries made at Imperial College London and the Francis Crick Institute by its co-founders Prof Ed Tate, Dr Andrew Bell and Dr Roberto Solari. The Company has raised an initial £4.5million in seed investment from Sofinnova Partners and Brandon Capital Partners. Myricx has the rights to key NMT discoveries, and composition-of-matter and use patents of its scientific co-founders through exclusive license agreements with Imperial College London.

Follow us on LinkedIn and Twitter

About Myristoylation 

Myristoylation is a lipid modification to a specific group of target proteins in a cell. It involves the attachment of myristic acid, a 14-carbon fatty acid, to a protein’s N-terminal glycine residue. This process is catalysed by the ubiquitous eukaryotic enzyme, N-myristoyltransferase (NMT), which uses myristoyl-coenzyme A (CoA) as a substrate.

Myristoylation is an irreversible change to proteins and plays a vital role in protein–protein interactions, targeting proteins to cytoplasmic and plasma membranes, and regulating cellular signalling pathways in several biological processes. It is also known to be involved in a range of diseases including cancer, inflammatory conditions, epilepsy and Alzheimer’s disease.

For Further information, please contact:

At the Company

Dr Roberto Solari, CEO, Myricx Pharma, info@myricxbio.com                                                                                                                     

Media Enquiries

Sue Charles, Charles Consultants, sue.charles59@outlook.com, +44 (0)7986 726585